By Rishika Sadam and Kashish Tandon HYDERABAD (Reuters) -Danish drugmaker Novo Nordisk launched its blockbuster weight-loss ...

Novo Nordisk A/S is hunting for more early-stage deals to pad its pipeline of next-generation obesity drugs, as the drugmaker ...

Combining bimagrumab with semaglutide caused 93% of weight loss to come from fat alone By comparison, about 72% of weight ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

A Chinese-developed GLP-1 drug is as effective as Ozempic or Zepbound, clinical trial says ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

Danish drugmaker Novo Nordisk officially launched its blockbuster weight-loss drug Wegovy on Tuesday as a once-a-week ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase ...

Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...

Drugmakers are racing to develop the next wave of obesity and diabetes medications that they hope will be even more powerful ...